Apitope: Developing Innovative Autoimmune therapies
Type of member: Incubation
Apitope have developed an innovative peptide therapy that could change the lives of sufferers of Multiple Sclerosis (MS) and with a platform that can be applied to other autoimmune conditions. The company is currently undertaking clinical trials of its MS therapy in partnership with a major pharmaceutical company. The staff and services at SETsquared Bristol supported the development of the company, which currently employs 22 people working in 2 countries.